Outpatient management of oral anticoagulation in atrial fibrillation

Critical Care Nursing Clinics of North America

Volumn 25, Issue 4, 2013, Pages 481-487

  Manning, Julia A ^a  

^a Woodlands North Houston Heart Center   (United States)

Author keywords

Atrial fibrillation; Oral anticoagulant; Outpatients; Stroke risk; Treatment

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN; MORPHOLINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE; RIVAROXABAN; THIOPHENE DERIVATIVE; WARFARIN;

AMBULATORY CARE; ANALOGS AND DERIVATIVES; ATRIAL FIBRILLATION; HUMAN; STROKE;

AMBULATORY CARE; ANTICOAGULANTS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; DABIGATRAN; FACTOR XA INHIBITORS; HUMANS; MORPHOLINES; PYRAZOLES; PYRIDONES; RIVAROXABAN; STROKE; THIOPHENES; WARFARIN;

EID: 84888066112     PISSN: 08995885     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccell.2013.09.002     Document Type: Review

References (18)

1. Mantha S., Cabral K., Ansell J. New avenues for anticoagulation in atrial fibrillation. Clin Pharmacol Ther 2013, 93:68-77.
2. Konkle B. Monitoring target specific anticoagulants. JThromb Thrombolysis 2013, 35:387-390.
3. Norgard N., DiNicolantonio J., Topping T., et al. Novel anticoagulants in atrial fibrillation stroke prevention. Ther Adv Chronic Dis 2013, 3:123-136.
4. O'Dell K., Igawa D., Hsin J. New oral anticoagulants for atrial fibrillation: a review of clinical trials. Clin Ther 2012, 34:894-901.
5. Gutierrez C., Blanchard D. Atrial fibrillation: diagnosis and treatment. Am Fam Physician 2011, 83:61-68.
6. Dittus C., Ansell J. The evolution of oral anticoagulation therapy. Prim Care 2013, 40:109-134.
7. Baker W., Cios D., Sander S., et al. Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. JManag Care Pharm 2009, 15:244-252.
8. Mani H., Kasper A., Lindhoff-Last E. Measuring the anticoagulant effects of target specific oral anticoagulants-reasons, methods and current limitations. JThromb Thrombolysis 2013, 36(2):187-194. Available at:, Accessed April 16, 2013. https://www.ncbi.nlm.nih.gov/pubmed/23512159.
9. Miller C., Grandi S., Shimony A., et al. Meta-analysis of efficacy and safety of neworal anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol 2012, 110(3):453-460. Available at:, Accessed April 16, 2013. http://dx.doi.org/10.1016/j.amjcard.2012.03.049.
10. Connolly S., Ezekowitz M., Yusuf S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. NEngl J Med 2009, 362:1139-1151.
11. Tun N., Oo T. Prevention and treatment of venous thromboembolism with new oral anticoagulants: a practical update for clinicians. Thrombosis 2013, 2013:183616. Available at:, Accessed April 16, 2013. http://dx.doi.org/10.1155/2013/183616.
12. Caterina R., Husted S., Wallentin L., et al. New oral anticoagulants in atrial fibrillation and acute coronary syndromes. JAm Coll Cardiol 2012, 59:1413-1425.
13. Patel M., Mahaffey K., Garg J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. NEngl J Med 2011, 365:883-891.
14. Granger C., Alexander J., McMurray J., et al. Apixaban versus warfarin in patients with atrial fibrillation. NEngl J Med 2011, 365:981-992.
15. Schulman S. New anticoagulants in atrial fibrillation management. Thromb Res 2013, 131(Suppl 1):S63-S66.
16. Becattini C., Vedovati M., Agnelli G. Old and new oral anticoagulants for venous thromboembolism and atrial fibrillation: a review of the literature. Thromb Res 2012, 129:392-400.
17. Yeung L., Miraflor E., Harken A. Confronting the chronically anticoagulated, acute care surgery patient as we evolve into the post-warfarin era. Surgery 2012, 153:308-315.
18. Skanes A. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol 2012, 28:125-136.